Hubert Wong1, Laura Vivian, Gabrielle Weiler, Guido Filler. 1. Department of Pediatrics, Division of Pediatric Nephrology, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.
Abstract
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) ranks among the most common genetic disorders. The development of end-stage renal failure usually is after the fourth decade of life. Angiotensin-converting enzyme (ACE) inhibitors often are used as agents to slow the progression of renal failure, although their effectiveness and starting point in ADPKD remain unclear. METHODS: We measured technetium 99m diethylenetriamine pentaacetic acid glomerular filtration rate (GFR) and serum cystatin C (Cys-C) levels in 18 children with ADPKD and 41 control patients. Data are given as mean +/- SD. Mean age was 9.8 +/- 5.9 years, mean height was 137.5 +/- 34.3 cm, and mean weight was 39.2 +/- 22.8 kg in the ADPKD group, not significantly different from controls, with an average age of 10.4 +/- 4.9 years, height of 138.0 +/- 26.1 cm, and weight of 38.0 +/- 16.8 kg. RESULTS: Mean serum creatinine levels did not differ between the ADPKD (0.6 +/- 0.2 mg/dL [51.1 +/- 20.4 micromol/L]) and control groups (0.7 +/- 0.2 mg/dL [59.8 +/- 15.3 micromol/L]; P = 0.19). Mean GFR was 142 +/- 33.2 mL/min/1.73 m2 in the ADPKD group, significantly greater than that in controls (110 +/- 12 mL/min/1.73 m2; P < 0.0001). Mean Cys-C level for the ADPKD group was 0.71 +/- 0.11 mg/L, significantly lower than that of controls (0.81 +/- 0.12 mg/L; P = 0.0011). No patient with ADPKD had hypertension, and only 1 patient had minimal microalbuminuria. Although renal length on ultrasound was significantly increased, there was no correlation between renal length and GFR or number of cysts. CONCLUSION: Therefore, the high GFR measurements represent early hyperfiltration in children and adolescents with ADPKD, which may give a rationale to start ACE inhibitor therapy.
BACKGROUND:Autosomal dominant polycystic kidney disease (ADPKD) ranks among the most common genetic disorders. The development of end-stage renal failure usually is after the fourth decade of life. Angiotensin-converting enzyme (ACE) inhibitors often are used as agents to slow the progression of renal failure, although their effectiveness and starting point in ADPKD remain unclear. METHODS: We measured technetium 99m diethylenetriamine pentaacetic acid glomerular filtration rate (GFR) and serum cystatin C (Cys-C) levels in 18 children with ADPKD and 41 control patients. Data are given as mean +/- SD. Mean age was 9.8 +/- 5.9 years, mean height was 137.5 +/- 34.3 cm, and mean weight was 39.2 +/- 22.8 kg in the ADPKD group, not significantly different from controls, with an average age of 10.4 +/- 4.9 years, height of 138.0 +/- 26.1 cm, and weight of 38.0 +/- 16.8 kg. RESULTS: Mean serum creatinine levels did not differ between the ADPKD (0.6 +/- 0.2 mg/dL [51.1 +/- 20.4 micromol/L]) and control groups (0.7 +/- 0.2 mg/dL [59.8 +/- 15.3 micromol/L]; P = 0.19). Mean GFR was 142 +/- 33.2 mL/min/1.73 m2 in the ADPKD group, significantly greater than that in controls (110 +/- 12 mL/min/1.73 m2; P < 0.0001). Mean Cys-C level for the ADPKD group was 0.71 +/- 0.11 mg/L, significantly lower than that of controls (0.81 +/- 0.12 mg/L; P = 0.0011). No patient with ADPKD had hypertension, and only 1 patient had minimal microalbuminuria. Although renal length on ultrasound was significantly increased, there was no correlation between renal length and GFR or number of cysts. CONCLUSION: Therefore, the high GFR measurements represent early hyperfiltration in children and adolescents with ADPKD, which may give a rationale to start ACE inhibitor therapy.
Authors: Sravanthi Lavu; Lisa E Vaughan; Sarah R Senum; Timothy L Kline; Arlene B Chapman; Ronald D Perrone; Michal Mrug; William E Braun; Theodore I Steinman; Frederic F Rahbari-Oskoui; Godela M Brosnahan; Kyongtae T Bae; Douglas Landsittel; Fouad T Chebib; Alan Sl Yu; Vicente E Torres; Peter C Harris Journal: JCI Insight Date: 2020-08-06
Authors: Alan S L Yu; Chengli Shen; Douglas P Landsittel; Jared J Grantham; Larry T Cook; Vicente E Torres; Arlene B Chapman; Kyongtae Ty Bae; Michal Mrug; Peter C Harris; Frederic F Rahbari-Oskoui; Tiange Shi; William M Bennett Journal: Kidney Int Date: 2019-03-04 Impact factor: 10.612
Authors: Arlene B Chapman; James E Bost; Vicente E Torres; Lisa Guay-Woodford; Kyongtae Ty Bae; Douglas Landsittel; Jie Li; Bernard F King; Diego Martin; Louis H Wetzel; Mark E Lockhart; Peter C Harris; Marva Moxey-Mims; Mike Flessner; William M Bennett; Jared J Grantham Journal: Clin J Am Soc Nephrol Date: 2012-02-16 Impact factor: 8.237
Authors: Ivana Pavik; Philippe Jaeger; Lena Ebner; Diane Poster; Fabienne Krauer; Andreas D Kistler; Katharina Rentsch; Gustav Andreisek; Carsten A Wagner; Olivier Devuyst; Rudolf P Wüthrich; Christoph Schmid; Andreas L Serra Journal: Clin J Am Soc Nephrol Date: 2011-12-22 Impact factor: 8.237
Authors: Melissa A Cadnapaphornchai; Kim McFann; John D Strain; Amirali Masoumi; Robert W Schrier Journal: Clin J Am Soc Nephrol Date: 2009-04 Impact factor: 8.237